Valsartan-SZ, 160 mg 30 pcs

Valsartan is an active specific angiotensin II receptor antagonist for oral administration. It selectively blocks the AT1 subtype receptors that are responsible for the effects of angiotensin II.

Indications

arterial hypertension in adults; chronic heart failure (functional class II–IV according to the NYHA classification), in adult patients receiving standard therapy with one or more drugs from the following pharmacotherapeutic groups: diuretics, cardiac glycosides, as well as ACE inhibitors or beta-blockers (the use of each of these drugs is not mandatory).

Pharmacological effect

Valsartan is an active specific angiotensin II receptor antagonist intended for oral administration. Selectively blocks receptors of the AT1 subtype, which are responsible for the effects of angiotensin II.

Special instructions

Patients with impaired renal function Avoid simultaneous use of ARB II (including the drug Valsartan-SZ) or ACE inhibitors with aliskiren in patients with severely impaired renal function (GFR < 30 ml/min).

Active ingredient

Valsartan

Composition

active ingredient:

Pregnancy

Like any other drug that affects the RAAS, Valsartan-SZ should not be used in women planning pregnancy.

Contraindications

hypersensitivity to any of the components of the drug; severe liver dysfunction (more than 9 points on the Child-Pugh scale), biliary cirrhosis and cholestasis;

Side Effects

In patients with hypertension in controlled clinical trials, the incidence of AEs was comparable to placebo. There are no data on the dependence of the frequency of any of the AEs on the dose or duration of treatment, as well as gender, age or race. The safety profile of Valsartan-SZ in patients with arterial hypertension aged 6 to 18 years does not differ from the safety profile of valsartan in adult patients.

Interaction

It has been established that during monotherapy with valsartan there are no clinically significant interactions with the following drugs: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine, glibenclamide. Dual blockade of the RAAS when using ARA II, ACE inhibitors or aliskiren Concomitant use of ARA II (including the drug Valsartan-SZ) with other drugs that affect the RAAS is associated with an increased incidence of arterial hypotension, hyperkalemia and changes in renal function compared with monotherapy.

Overdose

Symptoms: marked decrease in blood pressure, which can lead to depression of consciousness, collapse and/or shock.

Recommendations for use

Orally, without chewing, regardless of food intake, with water. Adults Arterial hypertension. The drug can be prescribed in doses of 40, 80, 160 and 320 mg. The recommended initial dose of Valsartan-SZ is 80 mg/day, regardless of the race, age and gender of the patient. The antihypertensive effect is observed in the first 2 weeks of treatment; the maximum effect develops after 4 weeks. For those patients who fail to achieve an adequate therapeutic response, the daily dose of Valsartan-SZ can be gradually increased to a maximum daily dose of 320 mg or it is necessary to additionally use diuretics. CHF. The recommended initial dose of Valsartan-SZ is 40 mg 2 times a day.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C.

Shelf life

3 years

Manufacturer

North Star NAO, Russia